These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 15687111

  • 1. Clinical outcomes and C2 cyclosporin monitoring in maintenance renal transplant recipients: 1 year follow-up study.
    Marcén R, Villafruela JJ, Pascual J, Teruel JL, Ocaña J, Tenorio MT, Burgos FJ, Ortuño J.
    Nephrol Dial Transplant; 2005 Apr; 20(4):803-10. PubMed ID: 15687111
    [Abstract] [Full Text] [Related]

  • 2. Evolution of the absorption profile of cyclosporine A in renal transplant recipients: a longitudinal study of the de novo and maintenance phases.
    Büchler M, Chadban S, Cole E, Midtvedt K, Thervet E, Prestele H, Keown P.
    Nephrol Dial Transplant; 2006 Jan; 21(1):197-202. PubMed ID: 16204301
    [Abstract] [Full Text] [Related]

  • 3. Early cyclosporine C0 and C2 monitoring in de novo kidney transplant patients: a prospective randomized single-center pilot study.
    Kyllönen LE, Salmela KT.
    Transplantation; 2006 Apr 15; 81(7):1010-5. PubMed ID: 16612277
    [Abstract] [Full Text] [Related]

  • 4. C2 monitoring in maintenance renal transplant recipients: is it worthwhile?
    Midtvedt K, Fauchald P, Bergan S, Høieggen A, Hallan S, Svarstad E, Bergrem H, Eriksen BO, Pfeffer PF, Dalen I, Leivestad T.
    Transplantation; 2003 Oct 27; 76(8):1236-8. PubMed ID: 14578761
    [Abstract] [Full Text] [Related]

  • 5. Limitations of cyclosporine C2 monitoring in pediatric heart transplant recipients.
    Hmiel SP, Canter C, Shepherd R, Lassa-Claxton S, Nadler M.
    Pediatr Transplant; 2007 Aug 27; 11(5):524-9. PubMed ID: 17631021
    [Abstract] [Full Text] [Related]

  • 6. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO, Ehlermann P, Koch A, Remppis A, Katus HA, Dengler TJ.
    Clin Ther; 2006 Jun 27; 28(6):893-905. PubMed ID: 16860172
    [Abstract] [Full Text] [Related]

  • 7. Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion.
    Thervet E, Pfeffer P, Scolari MP, Toselli L, Pallardó LM, Chadban S, Pilmore H, Connolly J, Buchler M, Schena FP, Carreño CA, Dandavino R, Cole E.
    Transplantation; 2003 Sep 27; 76(6):903-8. PubMed ID: 14508352
    [Abstract] [Full Text] [Related]

  • 8. Association between cyclosporine concentrations at 2 hours post-dose and clinical outcomes in de novo lung transplant recipients.
    Akhlaghi F, Gonzalez L, Trull AK.
    J Heart Lung Transplant; 2005 Dec 27; 24(12):2120-8. PubMed ID: 16364860
    [Abstract] [Full Text] [Related]

  • 9. Three-years experience with Neoral C2 monitoring adjusted to a target range of 500-600 ng/ml in long-term renal transplant recipients receiving dual immunosuppressive therapy.
    Carstens J.
    Scand J Urol Nephrol; 2008 Dec 27; 42(3):286-92. PubMed ID: 18432535
    [Abstract] [Full Text] [Related]

  • 10. Monitoring of cyclosporine 2-hour post-dose levels in heart transplantation: improvement in clinical outcomes.
    Delgado DH, Rao V, Hamel J, Miriuka S, Cusimano RJ, Ross HJ.
    J Heart Lung Transplant; 2005 Sep 27; 24(9):1343-6. PubMed ID: 16143255
    [Abstract] [Full Text] [Related]

  • 11. Cyclosporine profiling with C2 and C0 monitoring improves outcomes after heart transplantation.
    Barnard JB, Thekkudan J, Richardson S, Bittar MN, Martyszczuck R, Hasan J, Khasati N, Keevil B, Yonan N.
    J Heart Lung Transplant; 2006 May 27; 25(5):564-8. PubMed ID: 16678036
    [Abstract] [Full Text] [Related]

  • 12. Experience with cyclosporine: approaching the therapeutic window for C2 levels in maintenance kidney transplant recipients.
    Di Paolo S, Teutonico A, Infante B, Stallone G, Schena A, Grandaliano G, Battaglia M, Di Tonno P, Schena FP.
    Transplant Proc; 2004 Mar 27; 36(2 Suppl):434S-436S. PubMed ID: 15041381
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
    Krämer BK, Montagnino G, Del Castillo D, Margreiter R, Sperschneider H, Olbricht CJ, Krüger B, Ortuño J, Köhler H, Kunzendorf U, Stummvoll HK, Tabernero JM, Mühlbacher F, Rivero M, Arias M, European Tacrolimus vs Cyclosporin Microemulsion Renal Transplantation Study Group.
    Nephrol Dial Transplant; 2005 May 27; 20(5):968-73. PubMed ID: 15741208
    [Abstract] [Full Text] [Related]

  • 14. C2 monitoring of cyclosporine in stable renal transplant patients results in lower costs and improved renal function.
    Domínguez J, Fuenzalida D, Norambuena R, Pais E, Cortes Monroy G, Llanos R.
    Transplant Proc; 2005 Apr 27; 37(3):1583-5. PubMed ID: 15866680
    [Abstract] [Full Text] [Related]

  • 15. Comparison of cyclosporine concentrations 2 hours post-dose determined using 3 different methods and trough level in pediatric renal transplantation.
    Rodríguez E, Delucchi MA, Cano F, Valdebenito S, Castillo MC, Villegas R.
    Transplant Proc; 2005 Oct 27; 37(8):3354-7. PubMed ID: 16298594
    [Abstract] [Full Text] [Related]

  • 16. Assessment of cyclosporine pharmacokinetic parameters to facilitate conversion from C0 to C2 monitoring in heart transplant recipients.
    Davies RA, Veinot JP, Williams K, Haddad H, Baker A, Donaldson J, Pugliese C, Struthers C, Masters RG, Hendry PJ, Mesana T.
    Transplant Proc; 2007 Dec 27; 39(10):3334-9. PubMed ID: 18089382
    [Abstract] [Full Text] [Related]

  • 17. C2 is superior to C0 as predictor of renal toxicity and rejection risk profile in stable heart transplant recipients.
    Caforio AL, Tona F, Piaserico S, Gambino A, Feltrin G, Fortina AB, Angelini A, Alaibac M, Bontorin M, Calzolari D, Peserico A, Thiene G, Iliceto S, Gerosa G.
    Transpl Int; 2005 Jan 27; 18(1):116-24. PubMed ID: 15612993
    [Abstract] [Full Text] [Related]

  • 18. Target range maximum of cyclosporine blood concentration two hours post dose in stable liver transplant patients.
    Li J, Dahmen U, Beckebaum S, Cicinnati V, Valentin-Gamazo C, Frilling A, Malago M, Broelsch CE.
    Eur J Med Res; 2006 Apr 28; 11(4):139-45. PubMed ID: 16720277
    [Abstract] [Full Text] [Related]

  • 19. Cyclosporine dose reduction in stable renal transplant patients with high C2 level: simplified method of single C2 measurement and individualization of C0 target.
    Higgins RM, Kanji H, Hernon M, Harrison P, Lam FT, Kashi SH.
    Transpl Int; 2005 Jul 28; 18(7):806-10. PubMed ID: 15948859
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of changing from cyclosporine C0 to C2 monitoring in stable recipients following renal transplantation: a prospective cohort study.
    Zhang Y, Zhang XD, Wang Y.
    Transplant Proc; 2011 Dec 28; 43(10):3697-701. PubMed ID: 22172829
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.